A case of phosphaturic mesenchymal tumour (mixed connective tissue variant) that developed in the subcutaneous tissue of a patient with oncogenic osteomalacia and produced fibroblast growth factor 23 [9]

British Journal of Dermatology

Volumn 157, Issue 1, 2007, Pages 198-200

  Oka, M ^a   Kamo, T ^a   Sasaki, E ^a   Kaji, H ^a   Nishizawa, H ^a   Imanishi, Y ^b   Nishigori, C ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; FIBROBLAST GROWTH FACTOR 23; PHOSPHATE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANGIOGENESIS; CASE REPORT; CELL SHAPE; CONNECTIVE TISSUE; HISTOPATHOLOGY; HUMAN; HYPERPARATHYROIDISM; HYPOPHOSPHATEMIA; LETTER; MALE; MESENCHYMOMA; OSTEOMALACIA; PHOSPHATURIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINDLE CELL; STELLATE CELL; SUBCUTANEOUS FAT; SUBCUTANEOUS TISSUE TUMOR; TREATMENT RESPONSE; VITAMIN BLOOD LEVEL;

FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MESENCHYMOMA; MIDDLE AGED; OSTEOMALACIA; SKIN NEOPLASMS;

EID: 34250656889     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.07940.x     Document Type: Letter

References (10)

1. Nelson AE, Robinson BG, Mason RS. Oncogenic osteomalacia: is there a new phosphate regulating hormone? Clin Endocrinol 1997 47 : 635 42.
2. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001 98 : 6500 5.
3. White KE, Jonsson KB, Carn G et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 2001 86 : 497 500.
4. Nelson AE, Bligh RC, Mirams M et al. Fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. J Clin Endocrinol Metab 2003 88 : 4088 94.
5. Takeuchi Y, Suzuki H, Ogura S et al. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab 2004 89 : 3979 82.
6. Jonsson KB, Zahradnik R, Larsson T et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003 348 : 1656 63.
7. Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumors. Cancer 1987 59 : 1442 54.
8. Folpe AL, Fanburg-Smith JC, Billings SD et al. Most osteomalacia- associated mesenchymal tumors are a single histopathologic entity. Am J Surg Pathol 2004 28 : 1 30.
9. Yamazaki Y, Okazaki R, Shibata M et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002 87 : 4957 60.
10. Kobayashi K, Imanishi Y, Koshiyama H et al. Expression of FGF23 is correlated with serum phosphate level in isolated fibrous dysplasia. Life Sci 2006 78 : 2295 301.